Exelixis reports Q2 rev. below consensus, net product revenues 2% lower YoY.

• Pomerantz LLP investigates Exelixis securities fraud claims • Investors advised to contact Danielle Peyton • Exelixis reports Q2 2025 financial results • Net product revenues for cabozantinib 2% below consensus estimate • Exelixis discloses emerging data from clinical trials • Bloomberg financial analyst focuses on digital data • Class action information available on Pomlaw.com • Bloomberg financial analyst provides summary under 100 words • Digital data focus on financial performance and clinical trials

New York, July 2, 2025 — Pomerantz LLP has launched an investigation into potential securities fraud claims against Exelixis, Inc. (NASDAQ: EXEL). Investors are advised to contact Danielle Peyton at 646-581-9980, ext. 7980, for more information. The investigation focuses on whether Exelixis and its officers or directors have engaged in unlawful business practices [1].

On July 28, 2025, Exelixis reported its second-quarter 2025 financial results, which included net product revenues for cabozantinib approximately 2% below the consensus estimate of $531.3 million. The company also disclosed that it has decided not to proceed with the phase 3 portion of the STELLAR-305 study in advanced squamous cell carcinoma of the head and neck due to emerging data, competition, and other commercial opportunities [2].

Following the announcement, Exelixis's stock price fell by $7.45 per share, or 16.78%, to close at $36.94 per share on July 29, 2025 [1]. Pomerantz LLP, known for its expertise in securities class actions, is investigating potential claims on behalf of investors [1].

Exelixis’s quarterly performance highlights strong growth in its cabozantinib franchise, with revenues of $568.3 million, up 11% year-over-year. The company's net income showed an 18% decrease year-over-year but improved by 16% compared to the previous quarter. The company continues to advance its pipeline, with positive results from the STELLAR-303 trial and plans to discuss these results with regulators [3].

Investors can find more information about joining the class action on Pomlaw.com [1]. Bloomberg financial analysts have summarized Exelixis's Q2 2025 performance, focusing on financial performance and clinical trial data.

References:
[1] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-exelixis-inc-----exel-302525753.html
[2] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-exelixis-inc---exel-302527422.html
[3] https://www.investing.com/news/company-news/exelixis-q2-2025-presentation-slides-cabozantinib-franchise-grows-19-yoy-93CH-4194716